Few data exist concerning the effect of obesity on the pharmacokinetic parameters of vancomycin. The purpose of this investigation was to assess the effect of obesity on vancomycin pharmacokinetic parameters in 95 nonobese and 135 obese adult patients (age range, 18 to 92 years) receiving vancomycin. All subjects had normal renal function as defined by a creatinine concentration in serum of c1.5 mg/dl (mean estimated creatinine clearance 1 standard deviation, 76 34; range, 23 to 215 ml/min). Vancomycin concentrations in serum were determined by the fluorescence polarization immunoassay. All data for vancomycin concentration in serum versus time for each course of therapy were fitted by using a two-compartment Bayesian forecasting program. Subjects were stratified into nine groups on the basis of the percent difference between actual body weight (ABW) and lean body weight (LBW) (>-10o, -10 to 0%o, >0 to 10%,, > 10 to 20%o, >20 to 30%o, >30 to 40o, >40 to 50%, >50 to 60%, >60%). Analysis of variance with post hoc Scheffe's testing revealed that statistically significant differences occurred in terminal disposition half-life (t1/211) between the extremes of modestly obese (group 4) and morbidly obese (group 9, P < 0.05) patients. Similar analysis with distribution volume (V') identified significant differences in patients at or near their LBW (groups 2 to 4) and patients who were morbidly obese (groups 8 and 9, P < 0.05). Multiple regression models for the pharmacokinetic parameters V, tl/2", and vancomycin total body clearance were developed to assess the joint predictive power of LBW, ABW, and percent over LBW, controlling for the effects of age, initial creatinine concentration in serum, initial creatinine clearance, and gender. In the final model for V, both ABW and percent over LBW were independent and significant predictors. For total body clearance, only ABW was significant and predictive. Percent over LBW was a significant and independent predictor of t,12,. LBW is not predictive of these pharmacokinetic parameters and should not be used for initial dosing. On the basis of these data, ABW appears to be superior to LBW for calculating initial dose requirements for vancomycin.
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Vancomycin is presently considered to be the drug of choice for methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections (7, 8, 12) . Several investigators have suggested that peak and trough concentrations in serum be monitored and appropriately adjusted during therapy (12, 27, 28, 30) . The value of such monitoring has been extensively debated in the literature and is beyond the scope of this report (11, 27) .
A variety of pharmacokinetic models and dosing methods have been proposed for prospective dosage adjustment of vancomycin (24, 34) . Virtually all of these methods are configured to adjust for age-or disease-related changes in renal function. None of the current vancomycin dosing methods adjusts dosage on the basis of the extent of obesity.
Blouin et al. studied six morbidly obese patients and four patients of normal body weight and concluded that total body weight should be used in the determination of vancomycin dosing (3). Conclusions drawn from this small study sample must be considered preliminary. A study of a larger number of patients is needed to determine whether lean (LBW) or actual (ABW) body weight or some hybrid (lean plus a percent of adipose) body weight parameter should be The purposes of this investigation were (i) to determine whether obesity has a significant influence on the pharmacokinetic parameters of vancomycin in a large patient sample and (ii) to determine whether additional adjustments in vancomycin dosage calculations are required as a result of obesity. Vancomycin concentrations in serum (range, 0.6 to 100 mg/liter) were measured in our laboratory by using a fluorescence polarization immunoassay (TDx; Abbott Laboratories, Irving, Tex.). Interassay and intraassay coefficients of variation were 6.1 and <4.7%, respectively. All data for vancomycin concentration in serum versus time for each patient, either three postinfusion levels after the initial dose plus a follow-up trough/peak determination or two trough/ peak determinations (i.e., four samples), along with patientspecific vancomycin dosing history were entered into a commercially available pharmacokinetic software package, Abbottbase Pharmacokinetic Systems (Abbott Laboratories). These data were fitted to a two-compartment pharmacokinetic model previously described by Rodvold and colleagues which incorporates a Bayesian feedback loop (26) .
MATERIALS AND METHODS
The central compartment volume (V1) was assumed to be 0.21 liters/kg of ABW. Two-compartment pharmacokinetic microconstants K12 and K21 were assumed to be 1.12 Hr-1 and 0.48 Hr-1, respectively. Vancomycin clearance was calculated by using the following previously described regression equation ( (6) . Bayesian feedback was used to refine pharmacokinetic parameter estimates with patient-specific data for vancomycin concentration in serum versus time as previously described. Fractional standard deviation was set at 20% for V1, K12, K21, and nonrenal vancomycin clearance.
Fractional standard deviation was set at 33% for the slope of the regression equation.
Patients were retrospectively stratified on the basis of the percent difference between their ABW and LBW. Nine patient groups were delineated, with differences between ABW and LBW of >-10%, -10 to 0%, >0 to 10%, >10 to 20%, >20 to 30%, >30 to 40%, >40 to 50%, >50 to 60%, and >60% (groups 1 through 9, respectively). LBW was calculated by the method of Devine Pharmacokinetic parameters were fitted to multiple linear regression models to control for the effect of demographic covariants available at the time of dosing. These demographic covariants included age, gender, initial creatinine concentration in serum, and initial creatinine clearance. Variables were entered by using stepwise forward entry algorithms. The order of variable entry into the final models was evaluated for each of the three models. Final models were selected by using the highest R2 to account for the majority of the variance in the dependent variables by all factors and covariants.
RESULTS
Of the 230 patients, 9 (4%) were more than 10% below their LBW, 47 (20%) were 10% or less below their LBW, 39 (17%) were at or < 10% above their LBW, and 28 (12%) were at or <20% above their LBW. The remaining 107 (47%) patients met the study definition of obesity. All statistical analyses were performed with commercial software (Statview; Brainpower, Inc., Calabasas, Calif.). There were no statistical differences in the mean patient age and creatinine clearance among the nine groups. There was a statistically significant difference in gender distribution between groups 7 and 9. Group 7 contained 8 males and 14 females, and group 9 contained 4 males and 10 females.
Mean (+ standard deviation) vancomycin pharmacokinetic parameters were determined for each of the nine groups and are reported in Table 1 . There were significant differences within the groups of obese patients. These differences were mainly between patient groups that were of low to near normal body weight versus those who were morbidly obese. Analysis of patients for which the ABW exceeded the LBW by 30% or more (groups 6 to 9) revealed a weaker correlation between V and percent over LBW (r = 0.65) compared with all weight groups. This difference was not statistically significant.
In order to determine whether obesity has a significant influence on the vancomycin pharmacokinetic parameters t/2~,3 CL, and V, weight was examined as a continuous variable. Patient demographic variables were entered into multiple regression models. The final regression model for V is presented in Table 2 . Both ABW and percent over LBW were significant and independent predictors of V. In addition to the body mass parameter, age was also found to be an independent predictor of V. Initial creatinine concentration in serum, initial creatinine clearance, LBW, and gender were not significant predictors and were not included in the final V model. Table 3 presents the final regression model for CL. After adjusting for the effects of age, gender, initial creatinine concentration in serum, and initial creatinine clearance, ABW was the only body mass parameter that was a significant predictor of CL. Additionally, significant predictors of CL were age and initial creatinine concentration in serum.
The final regression model for tl2, is presented in Table 4 (5, 15, 26) . The validity of the method used in this study has been determined by our own intensive internal examination and independently confirmed by other investigators (15, 26) .
The pharmacokinetics of vancomycin have also been studied in a variety of populations. Both normal volunteers and patient populations have been studied (13, 20, 28) . Patients have been evaluated on the basis of normal or abnormal renal function (13, 20, 23, 28) . Numerous studies characterizing vancomycin disposition in both hemodialysis and peritoneal dialysis patients have been published (2, 17, 19, 21, 33) . Patients have also been characterized on the basis of normal or abnormal hepatic function (4) . The effect of age on the pharmacokinetics of vancomycin has also been extensively studied (1, 9, 14, 16, 22, 31, 32) . Vancomycin pharmacokinetics in unique patient populations such as burn patients and intravenous drug abusers have also been characterized (29) . At the present time, there is an extremely limited amount of data characterizing the pharmacokinetics of vancomycin in obese patients (3). Blouin's study repre- 
